Blood CEA levels for detecting recurrent colorectal cancer

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Nicholson, Brian D ^a   Shinkins, Bethany ^b   Pathiraja, Indika ^a   Roberts, Nia W ^c   James, Tim J ^d   Mallett, Susan ^e   Perera, Rafael ^a   Primrose, John N ^f   Mant, David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

CANCER RECURRENCE; CANCER SURGERY; CLINICAL PRACTICE; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSITIVITY AND SPECIFICITY; STANDARD; SYSTEMATIC REVIEW; BLOOD; COLORECTAL NEOPLASMS; META ANALYSIS; TUMOR RECURRENCE;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; SENSITIVITY AND SPECIFICITY;

EID: 84965183880     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011134.pub2     Document Type: Review

References (316)

1. Banaszkiewicz Z, Jarmocik P, Frasz J, Tojek K, Mrozowski M, Jawien A. Usefulness of CEA concentration measurement and classic colonoscopy in follow-up after radical treatment of colorectal cancer. Polski Przeglad Chirurgiczny 2011 Jun;83(6):310-8.
2. Barillari P, Bolognese A, Chirletti P, Cardi M, Sammartino P, Stipa V. Role of CEA, TPA, and Ca 19-9 in the early detection of localized and diffuse recurrent rectal cancer. Diseases of the Colon and Rectum 1992 May;35(5):471-6.
3. Beart RW Jr, Metzger PP, O'Connell MJ, Schutt AJ. Postoperative screening of patients with carcinoma of the colon. Diseases of the Colon and Rectum 1981;24(8):585-8.
4. Bjerkeset T, Orjasaeter H, Soreide O. The role of carcinoembryonic antigen (CEA) in routine investigation and postsurgical monitoring in patients with colorectal cancer. Surgical Research Communications 1988;2:205-12.
5. Carlsson U, Stewénius J, Ekelund G, Leandoer L, Nosslin B. Is CEA analysis of value in screening for recurrences after surgery for colorectal carcinoma?. Diseases of the Colon and Rectum 1983;26(6):369-73.
6. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Järvinen H, Haglund C. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biology 2004;25(5-6):228-34.
7. Carriquiry LA, Piñeyro A. Should carcinoembryonic antigen be used in the management of patients with colorectal cancer?. Diseases of the Colon and Rectum 1999;42(7):921-9.
8. Deveney KE, Way LW. Follow-up of patients with colorectal cancer. American Journal of Surgery 1984;148(6):717-22.
9. Engarås B. Individual cutoff levels of carcinoembryonic antigen and CA 242 indicate recurrence of colorectal cancer with high sensitivity. Diseases of the Colon and Rectum 2003;46(3):313-21.
10. Farinon AM, Sivelli R, Sianesi M, Zanella E. Carcinoembryonic antigen (CEA) test associated with colonoscopy: a monitoring method for the early detection of recurrent colorectal carcinoma. Surgery in Italy 1980;20(3):190-8.
11. Fezoulidis I, Imhof H, Karner-Hanusch J, Teleky B, Wunderlich M, Schiessel R. The value of computed tomography after operation of carcinoma of the rectum. Digitale Bilddiagnostik 1987;7(4):194-8.
12. Fucini C, Tommasi SM, Rosi S, Malatantis G, Cardona G, Panichi S, et al. Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca 19-9 analysis and second-look surgery. Diseases of the Colon and Rectum 1987;30(4):273-7.
13. Graffner H, Hultberg B, Johansson B, Möller T, Petersson BG. Detection of recurrent cancer of the colon and rectum. Journal of Surgical Oncology 1985;28(2):156-9.
14. Hara M, Kanemitsu Y, Hirai T, Komori K, Kato T. Negative serum carcinoembryonic antigen has insufficient accuracy for excluding recurrence from patients withDukes C colorectal cancer: analysis with likelihood ratio and posttest probability in a follow-up study. Diseases of the Colon and Rectum 2008;51(11):1675-80.
15. Hara M, Sato M, Takahashi H, Takayama S, Takeyama H. Does serum carcinoembryonic antigen elevation in patients with postoperative stage II colorectal cancer indicate recurrence. Comparison with stage III. Journal of Surgical Oncology 2010;102(2):154-7.
16. Hine KR, Dykes PW. Serum CEA testing in the post-operative surveillance of colorectal carcinoma. British Journal of Cancer 1984;49(6):689-93.
17. Irvine T, Scott M, Clark CI. A small rise in CEA is sensitive for recurrence after surgery for colorectal cancer. Colorectal Diseases 2007;9(6):527-31.
18. Johnson JA, Giercksky KE. [Colorectal cancer recurrence. Early diagnosis by determination of a carcinoembryonic antigen in the serum]. Tidsskrift for Den Norske Laegeforening 1985;105(29):2044-6.
19. Jubert AV, Talbott TM, Maycroft TM. Characteristics of adenocarcinomas of the colorectum with low levels of preoperative plasma carcinoembryonic antigen (CEA). Cancer 1978;42(2):635-9.
20. Kanellos I, Zacharakis E, Demetriades H, Christoforidis E, Kanellos D, Pramateftakis MG, et al. Value of carcinoembryonic antigen assay in predicting hepatic metastases, local recurrence, and survival after curative resection of colorectal cancer. Surgery Today 2006;36(10):879-84.
21. Kato K, Morimoto T, Kato T, Yasue M, Takagi H, Kito T, et al. CEA assays in postoperative detection of recurrent colorectal carcinoma (author's transl). Nihin Gan Chyryo Gakkai Shi 1980;15(7):1137-42.
22. Kim HS, Lee MR. Diagnostic accuracy of elevated serum carcinoembryonic antigen for recurrence in postoperative stage II colorectal cancer patients: comparison with stage III. Annals of Coloproctology 2013;29(4):155-9.
23. Kohler JP, Simonowitz D, Paloyan D. Preoperative CEA level: a prognostic test in patients with colorectal carcinoma. The American Surgeon 1980;46(8):449-52.
24. Koizumi F, Odagiri H, Fujimoto H, Kawamura T, Ishimori A. [Clinical evaluation of four tumor markers (CEA, TPA, CA50 and CA72-4) in colorectal cancer]. Rinsho Byori -Japanese Journal of Clinical Pathology 1992;40(5):523-8.
25. Körner H, Söreide K, Stokkeland PJ, Söreide JA. Diagnostic accuracy of serum-carcinoembryonic antigen in recurrent colorectal cancer: a receiver operating characteristic curve analysis. Annals of Surgical Oncology 2007 Feb;14(2):417-23.
26. Li Destri G, Greco S, Rinzivillo C, Racalbuto A, Curreri R, Di Cataldo A. Monitoring Carcinoembryonic Antigen in Colorectal Cancer: Is it Still Useful?. Surgery Today 1998;28(12):1233-6.
27. Lucha PA Jr, Rosen L, Olenwine JA, Reed JF 3rd, Riether RD, Stasik JJ Jr, et al. Value of carcinoembryonic antigen monitoring in curative surgery for recurrent colorectal carcinoma. Diseases of the Colon and Rectum 1997;40(2):145-9.
28. Luporini G, Mangiarotti F, Fraschini P, Labianca R, Tassi GC, De Barbieri A. [Importance of the analysis of the carcinoembryonic antigen in clinical oncology]. Minerva Medica 1979;70(2):127-34.
29. Mach JP, Vienny H, Jaeger P, Haldemann B, Egely R, Pettavel J. Long-term follow-up of colorectal carcinoma patients by repeated CEA radioimmunoassay. Cancer 1978;42(3 Suppl):1439-47.
30. Mackay AM, Patel S, Carter S, Stevens U, Laurence DJ, Cooper EH, et al. Role of serial plasma C.E.A. assays in detection of recurrent and metastatic colorectal carcinomas. British Medical Journal 1974 Nov;4(5941):382-5.
31. Mariani G, Carmellini M, Bonaguidi F, Benelli MA, Toni MG. Serum CEA Monitoring in the follow-up of Colorectal Cancer Patients with negative preoperative Serum CEA. European Journal of Cancer 1980;16(8):1099-103.
32. McCall JL, Black RB, Rich CA, Harvey JR, Baker RA, Watts JM, et al. The Value of serum carcinoembryonic antigen in predicting recurrent disease following curative resection of colorectal cancer. Diseases of the Colon and Rectum 1994;37(9):875-81.
33. Miles WF, Greig JD, Seth J, Sturgeon C, Nixon SJ. Raised carcinoembryonic antigen level as an indicator of recurrent disease in follow up of patients with colorectal cancer. British Journal of General Practice 1995;45(395):287-8.
34. Minton JP, Hoehn JL, Gerber DM, Horsley JS, Connolly DP, Salwan F, et al. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer 1985;55(6):1284-90.
35. Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh B, Kapoor R, et al. 18F-FDG PET-CT in evaluation of postoperative colorectal cancer patients with rising CEA level. Nuclear Medicine Communications 2011;32(9):789-93.
36. Nishida O, Shiroto H, Satoh N, Nakajima Y. Clnical evaluation of a combination assay of CEA, CA19-9 and TPA in patients with colorectal cancer. Japanese Journal of Cancer Clinics 1988;34(416):1096-1100.
37. Ochoa-Figueroa MA, Uña-Gorospe J, Allende-Riera A, Cárdenas-Negro JC, Muñoz-Iglesias J, Cabello-García D, et al. Utility of low dose (18)F-FDG PET-CT in patients with suspected colorectal carcinoma recurrence in conventional diagnostic methods. Revista Espanola de Medicina Nuclear e Imagen Molecular 2012;31(5):249-56.
38. Ohlsson B, Breland U, Ekberg H, Graffner H, Tranberg KG. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Diseases of the Colon and Rectum 1995;38(6):619-26.
39. Ohtsuka T, Nakafusa Y, Sato S, Kitajima Y, Tanaka M, Miyazaki K. Different roles of tumor marker monitoring after curative resections of gastric and colorectal cancers. Digestive Diseases and Sciences 2008;53(6):1537-43.
40. Park IJ, Choi GS, Lim KH, Kang BM, Jun SH. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level. Annals of Surgical Oncology 2009;16(11):3087-93.
41. Peng NJ, Hu C, King TM, Chiu YL, Wang JH, Liu RS. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography. Cancer Biotherapy & Radiopharmaceuticals 2013;28(6):479-87.
42. Seregni E, Bombardieri E, Bogni A, Crippa F, De Jager E, Buraggi GL. The role of serum carcinoembryonic antigen (CEA) in the management of patients with colorectal carcinoma: the experience of the Istituto Tumori of Milan. International Journal of Biological Markers 1992;7(3):167-70.
43. Staib L, Schirrmeister H, Reske SN, Beger HG. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. American Journal of Surgery 2000;180(1):1-5.
44. Steele G Jr, Ellenberg S, Ramming K, O'Connell M, Moertel C, Lessner H, et al. CEA monitoring among patients in multi-institutional adjuvant G.I. therapy protocols. Annals of Surgery 1982;196(2):162-9.
45. Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Annals of Surgical Oncology 2009;16(9):2516-23.
46. Tate H. Plasma CEA in the post-surgical monitoring of colorectal carcinoma. British Journal of Cancer 1982;46(3):323-30.
47. Tobaruela E, Enriquez JM, Diez M, Camunas J, Muguerza J, Granell J. Evaluation of serum carcinoembryonic antigen monitoring in the follow-up of colorectal cancer patients with metastatic lymph nodes and a normal preoperative serum level. International Journal of Biological Markers 1997;12(1):18-21.
48. Triboulet JP, Dessaint JP, Lagache G. [Diagnostic value of the assay of beta 2 microglobulin during the monitoring of surgically-treated colorectal cancers. Comparison with carcinoembryonic antigen]. Gastroenterologie Clinique et Biologique 1983;7(10):808-11.
49. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Diseases of the Colon and Rectum 1994;37(3):272-7.
50. Wood CB, Ratcliffe JG, Burt RW, Malcolm AJ, Blumgart LH. The clinical significance of the pattern of elevated serum carcinoembryonic antigen (CEA) levels in recurrent colorectal cancer. British Journal of Surgery 1980;67(1):46-8.
51. Yakabe T, Nakafusa Y, Sumi K, Miyoshi A, Kitajima Y, Sato S, et al. Clinical significance of CEA and CA19-9 in postoperative follow-up of colorectal cancer. Annals of Surgical Oncology 2010;17(9):2349-56.
52. Yu BM. Evaluation of combined CA-19-9 and CEA assay in monitoring recurrences and metastases of colorectal cancer. Zhonghua Wai Ke Za Zhi 1992;30(12):707-9.
53. Motamed-Khorasani A, Small-Howard A, Etemadi H, Beart H. A new strategy for the early detection of colorectal cancer recurrence. Gastrointestinal Cancers Symposium (ASCO). San Francisco, CA, USA, January 19 -21. 2012.
54. Ahmed H, Bashir H, Khalid Nawaz M, Faruqui Z, Saeed Kazmi A, Ali Syed A, et al. Early detection of recurrence of colorectal carcinoma on F18-FDG PET-CT and its correlation with other clinicopathological parameters. Nuclear Medicine Communications 2013;34(4):394-5.
55. Aitken K, Barbachano Y, Sharma B, Cunningham D, Cook G, Rao S. Elevated CEA level in the asymptomatic patient with normal conventional imaging: How useful is PET-CT for the detection of colorectal cancer recurrence? Gastrointestinal Cancers Symposium, San Francisco, CA, USA. Journal of Clinical Oncology. 2012.
56. Amin A, Reddy A, Wilson R, Jha M, Miranda S, Amin J. Unnecessary surgery can be avoided by judicious use of PET/CT scanning in colorectal cancer patients. Journal of Gastrointestinal Cancer 2012;43(4):594-8.
57. Arnaud JP, Simon P, Ollier JC, Koehl C, Adloff M. [Interest and limits of estimation of the carcinoembryonic antigen in colonic and rectal (author's transl)]. Journal de Chirurgie 1979;116(11):633-6.
58. Arnaud JP, Cervi C, Bergamaschi R, Tuech JJ. [Value of oncologic follow-up of patients operated for colorectal cancer. A prospective study of 1000 patients]. Journal de Chirurgie 1997;134(2):45-50.
59. Arriola E, Navarro M, Parés D, Muñoz M, Pareja L, Figueras J, et al. Imaging techniques contribute to increased surgical rescue of relapse in the follow-up of colorectal cancer. Diseases of the Colon and Rectum 2006;49(4):478-84.
60. Auer IO, Schmid L, Hoecht B. The clinical value of the plasma CEA level for postoperative detection of recurrence and metastases of carcinoma of the gastrointestinal tract [[German] Klinische Wertigkeit Der Plasmakonzentration Des Karzinoembryonalen Antigens Bei Der Postoperativen Verlaufskontrolle Von Karzinomen Des Verdauungstraktes]. Medizinische Klinik 1977;72(21):934-41.
61. Bakalakos EA, Burak WE, Young DC, Martin EW. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?. American Journal of Surgery 1999;177(1):2-6.
62. Barillari P, Ramacciato G, Manetti G, Bovino A, Sammartino P, Stipa V. Surveillance of colorectal cancer: effectiveness of early detection of intraluminal recurrences on prognosis and survival of patients treated for cure. Diseases of the Colon and Rectum 1996;39(4):388-93.
63. Beatty J, Romero C, Brown PW, Lawrence W, Jr, Terz JJ. Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer. Archives of Surgery 1979;114(5):563-7.
64. Beets G, Penninckx F, Schiepers C, Filez L, Mortelmans L, Kerremans R, et al. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer. British Journal of Surgery 1994;81(11):1666-70.
65. Bhatavdekar JM, Patel DD, Giri DD, Karelia NH, Vora HH, Ghosh N, et al. Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum. British Journal of Cancer 1992;66(5):977-80.
66. Bivins BA, Meeker WR Jr, Griffen WO Jr. CEA levels and prognosis in colon carcinoma. Journal of Surgical Oncology 1974;6(5):413-21.
67. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World Journal of Surgery 1984;8(3):279-86.
68. Borie F, Daurès JP, Millat B, Trétarre B. Cost and effectiveness of follow-up examinations in patients with colorectal cancer resected for cure in a French population-based study. Journal of Gastrointestinal Surgery 2004;8(5):552-8.
69. Brummendorf T, Anderer FA, Staab HJ, Hornung A, Kieninger G. [Carcinoembryonic antigen: diagnosis and tumor progression in gastrointestinal tumors]. Deutsche Medizinische Wochenschrift 1985;110(51-52):1963-8.
70. Brummendorf T, Anderer FA, Staab HJ, Hornung A, Kieninger G. [The doubling time of circulating CEA as an individual prognostic criterion of recurrence in patients with gastrointestinal cancers]. Klinische Wochenschrift 1986;64(2):63-9.
71. Bucci L, Benassai G, Santoro GA. Second look in colorectal surgery. Diseases of the Colon and Rectum 1994;37(2 Suppl):S123-6.
72. Camunas J, Enriquez JM, Devesa JM, Morales V, Millan I. Value of follow-up in the management of recurrent colorectal cancer. European Journal of Surgical Oncology 1991;17(5):530-5.
73. Cangemi V, Fiori E, Santeusanio G. The clinical usefulness of post-operative monitoring of plasmatic CEA in colorectal cancer [[Italian] Utilita clinica del monitoraggio post-operatorio del cea ematico nei cancri del colon e del retto]. Giornale di Chirurgia 1984;5(1):83-8.
74. Cangemi V, Volpino P, Fiori E. The role of tumour markers (CEA, TPA, CA 19-9) in colon and rectum carcinomas. Journal of Nuclear Medicine and Allied Sciences 1987;31(2):189-93.
75. Carl J, Bentzen SM, Norgaard-Pedersen B, Kronborg O. Modelling of serial carcinoembryonic antigen changes in colorectal cancer. Scandinavian Journal of Clinical & Laboratory Investigation 1993;53(7):751-5.
76. Carpelan-Holmström MA, Haglund CH, Järvinen HJ, Roberts PJ. Serum CA 242 and CEA detect different patients with recurrent colorectal cancer. Anticancer Research 1996;16(2):981-6.
77. Castells A, Bessa X, Daniels M, Ascaso C, Lacy AM, García-Valdecasas JC, et al. Value of postoperative surveillance after radical surgery for colorectal cancer: results of a cohort study. Diseases of the Colon and Rectum 1998;41(6):714-23.
78. Catania G, Basile F, Cardi F, Azzarello G, Mazzarino C, Campo M, et al. [Value of carcinoembryonic antigen (CEA) in the diagnosis and postoperative monitoring of patients with colorectal cancer]. Minerva Chirurgica 1981;36(9):569-80.
79. Chang AC, Warrena LR, Barretoa SG, Williams R. Differing serum CEA in primary and recurrent rectal cancer -a reflection of histology?. World Journal of Oncology 2012;3(2):59-63.
80. Chapman MA, Buckley D, Henson DB, Armitage NC. Preoperative carcinoembryonic antigen is related to tumour stage and long-term survival in colorectal cancer. British Journal of Cancer 1998;78(10):1346-9.
81. Chen CH, Hsieh MC, Lai CC, Yeh CY, Chen JS, Hsieh PS, et al. Lead time of carcinoembryonic antigen elevation in the postoperative follow-up of colorectal cancer did not affect the survival rate after recurrence. International Journal of Colorectal Disease 2010;25(5):567-71.
82. Cho YB, Chun HK, Yun HR, Lee WS, Yun SH, Lee WY. Clinical and pathologic evaluation of patients with recurrence of colorectal cancer five or more years after curative resection. Diseases of the Colon and Rectum 2007;50(8):1204-10.
83. Choi JS, Min JS. Significance of postoperative serum level of carcinoembryonic antigen (CEA) and actual half life of CEA in colorectal cancer patients. Yonsei Medical Journal 1997 Feb;38(1):1-7.
84. Colombo PL, Lovotti D, Franco F, Coronelli M, Bonacasa R. [Value of CEA in the early diagnosis of colorectal cancer recurrence in the light of second-look results]. Minerva Medica 1986;77(13):495-8.
85. Cossu F, Fodde M, Ledda P, Pisano G, Rombi GP, Scintu F, et al. [Prognostic value of CEA in postoperative monitoring of colorectal cancers]. Minerva Medica 1984;75(40):2373-80.
86. Dalton RSJ, Burn PR, Eyrebrook I. CT surveillance to detect colorectal cancer recurrence is the best option for possible curative resection. Colorectal Disease 2010;12(Suppl I):1-13.
87. S. Dash, A. Gupta. Clinical utility of FDG PET-CT in surveillance of patients with colorectal malignancy when serum CEA level is within normal range -A prospective study. European Journal of Nuclear Medical Molecular Imaging 2012;39(Suppl 2):S581.
88. De Brauw LM, Van de Velde CJH, Albers GHR, Zwaveling A. The value of follow-up after surgery for carcinoma of the colon. Nederlands Tijdschrift voor Geneeskunde 1987;131:496-500.
89. De Levin RW, Levin E. Correlation of single and serial CEA determinations with the clinical evolution of cancer patients. Archiv für Geschwulstforschung 1982;52(2):105-12.
90. De Salvo L, Razzetta F, Arezzo A, Tassone U, Bogliolo G, Bruzzone D, et al. Surveillance after colorectal cancer surgery. European Journal of Surgical Oncology. 1997;23(6):522-5.
91. Dhar P, Moore T, Zamcheck N, Kupchik HZ. Carcinoembryonic antigen (CEA) in colonic cancer. Use in preoperative and postoperative diagnosis and prognosis. JAMA 1972;221(1):31-5.
92. Di Cristofaro L, Scarpa M, Angriman I, Perissinotto E, Ruffolo C, Frego M, et al. Cost-effectiveness analysis of postoperative surveillance protocols following radical surgery for colorectal cancer. Acta Chirurgica Belgica 2012;112(1):24-32.
93. Engarås B, Kewenter J, Nilsson O, Wedel H, Hafström L. CEA, CA 50 and CA 242 in patients surviving colorectal cancer without recurrent disease. European Journal of Surgical Oncology 2001;27(1):43-8.
94. Farquharson AL, Genever AV, Belfield J, Hersey N, Amin SN, De Noronha R. PET-CT scan is a specific test for the detection of recurrent colorectal cancer but has limitations for patients with mucinous tumours. Colorectal Disease 2012;14(Suppl I):1-11.
95. Fernandes LC, Kim SB, Saad SS, Matos D. Value of carcinoembryonic antigen and cytokeratins for the detection of recurrent disease following curative resection of colorectal cancer. World Journal of Gastroenterololgy 2006;12(24):3891-4.
96. Filella X, Molina R. Use of CA 19-9 in the early detection of recurrences in colorectal cancer: comparison with CEA. Tumour Biology 1994;15(1):1-6.
97. Filiz AI, Sucullu I, Kurt Y, Karakas DO, Gulec B, Akin ML. Persistent high postoperative carcinoembryonic antigen in colorectal cancer patients--is it important?. Clinics (Sao Paulo) 2009;64(4):287-94.
98. Finlay IG, McArdle CS. Role of carcinoembryonic antigen in detection of asymptomatic disseminated disease in colorectal carcinoma. British Medical Journal (Clinical Research Edition) 1983;286(6373):1242-4.
99. Fiocchi F, Iotti V, Ligabue G, Malavasi N, Luppi G, Bagni B, et al. Role of carcinoembryonic antigen, magnetic resonance imaging, and positron emission tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer. Clinical Imaging 2011;35(4):266-73.
100. Florio MG, Artemisia A, Giorgianni G, Cogliandolo A, Giacobbe G, Manganaro T, et al. Recurrences in patients operated on by colorectal cancer. Diagnostic reliability of two tumour markers. Chirurgia Gastroenterologica 1988;22(4):475-7.
101. Fora AA, Patta AM, Attwood K, Wilding GE, Fakih M. Intensive radiographic and CEA screening and salvage resection in patients with stage II and III colorectal cancer. Journal of Clinical Oncology 2012;30(Supplement 4):abstract 405.
102. Forones NM, Tanaka M, Falcão JB. CEA as a prognostic index in colorectal cancer. Sao Paulo Medical Journal 1997 Nov-Dec;115(6):1589-92.
103. Forones NM, Tanaka M, Machado D. Increased carcinoembryonic antigen and absence of recurrence in monitoring colorectal cancer. Arquivos de Gastroenterologia 1998;35(2):100-3.
104. Fortner JG. Recurrence of colorectal cancer after hepatic resection. America Journal of Surgery 1988;155(3):378-82.
105. Fournier RS, Kilroy K, Alavi A. Correlation between FDG PET imaging results and plasma CEA levels in patients with suspected recurrent colon carcinoma. Journal of Nuclear Medicine 1999;40(5):241P.
106. Fucini C, Tommasi MS, Cardona G, Malatantis G, Panichi S, Bettini U. Limitations of CEA monitoring as a guide to second-look surgery in colorectal cancer follow-up. Tumori 1983;69(4):359-64.
107. Fucini C, Malatantis G, D'Elia M, Tommasi MS. CEA monitoring and recurrences in the active follow-up of rectal cancer operated for cure [[Italian] Monitoraggio del cea e recidive nel follow-up attivo del cancro del retto operato radicalmente]. Rivista Italiana di Colon-Proctologia 1984;3(1):37-45.
108. Fucini C, Rosi S, Herd-Smith A. Value and limitations of intensive follow-up after radical surgery for rectocolonic cancer [[Italian] Significato e limiti del follow up intensivo dopo intervento radicale per cancro del colon-retto]. Minerva Chirurgica 1985;40(11):783-6.
109. Gail MH. Evaluating serial cancer marker studies in patients at risk of recurrent disease. Biometrics 1981;37(1):67-78.
110. Gajdukevich IV, Kitaev AB, Sharapov GN, Byhovets IV, Turlaj DM. The value of biomolecular tumour markers in abdominal cancer recurrence. Techniques in Coloproctology 2010;14(1):75-6.
111. Gaudagni F. The clinical utility of serum tumor markers in the management of gastrointestinal cancer patients. Journal of Clinical Ligand Assay 1999;22(4):364-6.
112. Graham RA, Wang S, Catalano PJ, Haller DG. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Annals of Surgery 1998 Jul;228(1):59-63.
113. Gray BN, Walker C, Barnard R. Value of serial carcinoembryonic antigen determinations for early detection of recurrent cancer. Medical Journal of Australia 1981;1(4):177-8.
114. Griesenberg D, Nurnberg R, Bahlo M, Klapdor R. CEA, TPS, CA 19-9 and CA 72-4 and the fecal occult blood test in the preoperative diagnosis and follow-up after resective surgery of colorectal cancer. Anticancer Research 1999;19(4A):2443-50.
115. Grossetti D, De Certaines J, Trebuchet G. The value and limitations of carcinoembryonic antigen levels (CEA) in colorectal cancers [[French] Valeur et limites du dosage de l'antigene carcino-embryonnaire (Ace) dans les cancers colo-rectaux]. Annales de Chirurgie 1981;35(19):875-7.
116. Grossmann I, De Bock GH, Meershoek-Klein Kranenbarg WM, Van de Velde CJ, Wiggers T. Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. European Journal of Surgical Oncology 2007;33(2):183-7.
117. Haga S, Takahashi N, Kato H, Mori M, Umeda H, Azuhata H, et al. Study of serum CEA as an index for forecasting recurrence of colorectal carcinoma. Journal of Tokyo Women's Medical College 1990;60(2):163-6.
118. Hall NR, Finan PJ, Stephenson BM, Purves DA, Cooper EH. The role of CA-242 and CEA in surveillance following curative resection for colorectal cancer. British Journal of Cancer 1994 Sep;70(3):549-53.
119. Hara M, Sato M, Takahashi H, Takayama S, Takeyama H. Accuracy of monitoring serum carcinoembryonic antigen levels in postoperative stage III colorectal cancer patients is limited to only the first postoperative year. Surgery Today 2011 Oct;41(10):1357-62.
120. Herrera MA, Chu TM, Holyoke ED. Carcinoembryonic antigen (CEA) as a prognostic and monitoring test in clinically complete resection of colorectal carcinoma. Annals of Surgery 1976;183(1):5-9.
121. Hida J, Yasutomi M, Shindoh K, Kitaoka M, Fujimoto K, Ieda S, et al. Second-look operation for recurrent colorectal cancer based on carcinoembryonic antigen and imaging techniques. Diseases of the Colon and Rectum 1996;39(1):74-9.
122. Hohenberger P, Schlag PM, Gerneth T, Herfarth C. Pre-and postoperative carcinoembryonic antigen determinations in hepatic resection for colorectal metastases. Predictive value and implications for adjuvant treatment based on multivariate analysis. Annals of Surgery 1994;219(2):135-43.
123. Holt A, Nelson RA, Lai L. Surveillance with serial serum carcinoembryonic levels detect colorectal cancer recurrences in patients who are initial nonsecretors. American Surgeon 2010;76(10):1100-3.
124. Holubec L Jr, Pikner R, Topolcan O, Finek J, Holubec L Sen, Pecen L. The usefulness of tumor markers in patients with colorectal carcinoma for the detection of local recurrences and distant metastases. Coloproctology 2001;23:26-31.
125. Holyoke ED, Chu TM, Murphy GP. CEA as a monitor of gastrointestinal malignancy. Cancer 1975;35(3):830-6.
126. Holubec Jr. L, Pikner R, Topolcan O, Finek J, Holubec Sen L, Pecen L. The usefulness of tumor markers in patients with colorectal carcinoma for the detection of local recurrences and distant metastases. Coloproctology 2001;23(1):26-31.
127. Humphreys A, Cornish J, Stevenson J, Corr C, Billings P, Chandran P. Is a normal CEA false reassurance following curative resection for non metastatic colorectal cancer?. Colorectal Disease. Copenhagen: 6th Scientific and Annual Meeting of the European Society of Coloproctology, 2011; Vol. 13:36.
128. Huyghe J. CEA radioimmunoassay. Clinical applications in colorectal cancer. Acta Chirurgica Belgica 1983;83(2):77-88.
129. Iarumov N, Ignatov A, Viiachki I. [The pre-and postoperative monitoring of the immunological indices and tumor markers in colorectal carcinoma]. Khirurgiia 1998;51(3):42-8.
130. Indinnimeo M, Cicchini C, Stazi A, Ghini C, Alessandrini G, Reale MG. Carcinoembryonic antigen in recurrence of colorectal cancer. 23rd National Congress of the Societa-Italiana-di-Chirurgia-Oncologica (SICO), Perugia, Italy. 1999.
131. Ito K, Hibi K, Ando H, Hidemura K, Yamazaki T, Akiyama S, et al. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Japanese Journal of Clinical Oncology 2002;32(2):54-8.
132. Jaeger P, Pettavel J, Wuilleret B, Bertholet MM, Mach JP. [Value and limits of the determination of carcinoembryonic antigen (CEA) in postoperative evaluation of patients with colonic and rectal carcinomas]. Schweizerische Medizinische Wochenschrift Journal Suisse de Medecine 1975;105(46):1533-8.
133. Jiang R. [Clinical significance of serum CEA determination in the diagnosis of colorectal cancer]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1989;11(5):348-51.
134. Kanellos I, Zacharakis E, Demetriades H, Christoforidis E, Kanellos D, Pramateftakis MG, et al. Value of carcinoembryonic antigen assay in predicting hepatic metastases, local recurrence, and survival after curative resection of colorectal cancer. Surgery Today 2006;36(10):879-84.
135. Karesen R, Hertzberg J, Johannesen J, Thoresen BO, Orjasaeter H. Carcinoembryonic antigen in the diagnosis and follow-up of colorectal carcinoma. American Journal of Proctology, Gastroenterology & Colon & Rectal Surgery 1980;31(11):18-22.
136. Kawamura YJ, Tokumitsu A, Mizokami K, Sasaki J, Tsujinaka S, Konishi F. First alert for recurrence during follow-up after potentially curative resection for colorectal carcinoma: CA 19-9 should be included in surveillance programs. Clinical Colorectal Cancer 2010;9(1):48-51.
137. Kerr NA, Jha B, Edwards T, Karnati G, Mackey PM. The detection of colorectal cancer recurrence following curative resection. Colorectal Disease 2012;14(Suppl 1):12-40.
138. Khan K, Rathore M, Loughlin V, Tham TCK, Bhatti MI, Allen D, et al. Retrospective analysis of resected primary colorectal cancer revealed no correlation between node harvest and node involvement. European Journal of Cancer 2009;7(2-3):326.
139. Kimura O, Kaibara N, Nishidoi H, Okamoto T, Takebayashi M, Kawasumi H, et al. Carcinoembryonic antigen slope analysis as an early indicator for recurrence of colorectal carcinoma. Japanese Journal of Surgery 1986;16(2):106-11.
140. Kishimoto G, Murakami K, Con SA, Yamasaki E, Domeki Y, Tsubaki M, et al. [Follow-up after curative surgery for colorectal cancer: impact of positron emission tomography -computed tomography (PET/CT)]. Revista de Gastroenterologia del Peru 2010;30(4):328-33.
141. Koch M, McPherson TA, Morrish DW. Carcinoembryonic antigen: 3 years' experience in a cancer clinic. Canadian Medical Association Journal 1977 Apr 9;116(7):769-71.
142. Koch M, McPherson TA. Predictive value of plasma CEA in patients with colorectal carcinoma. Journal of Surgical Oncology 1979;12(4):319-25.
143. Koch M, Washer G, Gaedke H, McPherson TA. Carcinoembryonic antigen: usefulness as a postsurgical method in the detection of recurrence in Dukes stages B2 and C colorectal cancers. Journal of the National Cancer Institute 1982;69(4):813-5.
144. Koga H, Moriya Y, Akasu T, Fujita S. The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. European Journal of Surgical Oncology 1999;25(3):292-6.
145. Körner H, Söreide K, Stokkeland PJ, Söreide JA. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. Journal of Gastrointestinal Surgery 2005;9(3):320-8.
146. Kumara K, Aggarwalb D, Ardakanib A, Syedb M, Ingham Clark C. Efficacy of an intensive colorectal cancer follow-up programme. European Journal of Surgical Oncology 2011;37(11):997.
147. Lagache G, Dessaint JP, Triboulet JP. Indications for repeat operations for recurrence of rectocolic cancer: Contribution of serum carcino-embryonic antigen (CEA) levels [[French] Valeur du taux serique d'antigene carcino-embryonnaire (A.C.E.) dans l'indication de reintervention pour recidive de cancer colo-rectal]. Chirurgie -Memoires de l'Academie de Chirurgie 1980;106(5):322-34.
148. Lauterbach M, Dehne A, Hesse V, Hofig G. [CEA determination in the follow-up of colorectal cancers]. Zentralblatt fur Chirurgie 1987;112(15):968-74.
149. Lavin PT, Day J, Holyoke ED, Mittelman A, Chu TM. A statistical evaluation of baseline and follow-up carcinoembryonic antigen in patients with resectable colorectal carcinoma. Cancer. 1981;47(4):823-6.
150. Lechner P, Lind P, Goldenberg DM. Can postoperative surveillance with serial CEA immunoscintigraphy detect resectable rectal cancer recurrence and potentially improve tumor-free survival?. Journal of American College of Surgeons 2000;191(5):511-8.
151. Leventakos K, Lu SS, Perry DJ. Intensive CT scan surveillance for patients who have undergone curative intent treatment for colorectalcancer: The Medstar Washington Hospital Center experience. Journal of Clinical Oncology 2013;31(Suppl):abstract e14675.
152. Levy M, Lipska L, Visokai V, Veskrna K, Simsa J. Tumor markers in colorectal cancer relapse. Tumor Biology 2012;33(Suppl I):S15-S80.
153. Lipska L, Visokai V, Levy M, Svobodova S, Kormunda S, Finek J. Tumor markers in patients with relapse of colorectal carcinoma. Anticancer Research 2007;27(4A):1901-5.
154. Lipska L, Visokai V, Levy M. Resectability of colorectal cancer relapse. European Journal of Surgical Oncology 2010;36(9):876-7.
155. Lorenz M, Happ J, Hottenrott C, Maul FD, Baum RP, Hor G, et al. [Clinical evaluation of the tumor marker CA 19-9 in comparison with carcinoembryonic antigen (CEA) in surgical pre-and postoperative diagnosis]. Nuclear-Medizin 1986;25(1):9-14.
156. Lunde OC, Havig O. Clinical significance of carcinoembryonic antigen (CEA) in patients with adenocarcinoma in colon and rectum. Acta Chirurgica Scandinavica 1982;148(2):189-93.
157. Ma CJ, Hsieh JS, Wang WM, Su YC, Huang CJ, Huang TJ, et al. Multivariate analysis of prognostic determinants for colorectal cancer patients with high preoperative serum CEA levels: prognostic value of postoperative serum CEA levels. Kaohsiung Journal of Medical Sciences 2006;22(12):604-9.
158. Mach JP, Jaeger P, Bertholet MM, Ruegsegger CH, Loosli RM, Pettavel J. Detection of recurrence of large-bowel carcinoma by radioimmunoassay of circulating carcinoembryonic antigen (C.E.A.). Lancet 1974;2(7880):535-40.
159. Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Archives of Surgery 1995;130(10):1062-7.
160. Makis W, Kurzencwyg D, Hickeson M. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence. Clinical Imaging 2013;37(6):1094-7.
161. Mant D, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3-5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: FACS randomized controlled trial. Journal of Clinical Oncology. Chicago: Annual Meeting of the American Society of Clinical Oncology, ASCO, 2013; Vol. 20.
162. Martin EW, Jr, Kibbey WE, DiVecchia L, Anderson G, Catalano P, Minton JP. Carcinoembryonic antigen: clinical and historical aspects. Cancer 1976;37(1):62-81.
163. Martin EW Jr, Cooperman M, King G, Rinker L, Carey LC, Minton JP. A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer. American Journal of Surgery 1979;137(2):167-9.
164. Martin EW Jr, Cooperman M, Carey LC, Minton JP. Sixty second-look procedures indicated primarily by rise in serial carcinoembryonic antigen. Journal of Surgical Research 1980;28(5):389-94.
165. Marucci MM, Capussotti L, Molinaro G, Duglio A, Torossian K, Marini C. [Carcinoembryonic antigen in colorectal tumors. Prognostic evaluation and postoperative monitoring]. Minerva Chirurgica 1983;38(11):751-5.
166. May DJ, Richardson JRC, Saunders BW, Miles AJG. Intensive long term follow-up after T1 and T2 node negative colorectal cancer is not necessary. Colorectal Disease 2012;14:22-3.
167. Mazilu L, Ciufu N, Galan M, Suceveanu AI, Suceveanu AP, Parepa IR, et al. Postherapeutic follow-up of colorectal cancer patients treated with curative intent. Chirurgia 2012;107(1):55-8.
168. McCarthy SM, Barnes D, Deveney K, Moss AA, Goldberg HI. Detection of recurrent rectosigmoid carcinoma: prospective evaluation of CT and clinical factors. American Journal of Roentgenology 1985;144(3):577-9.
169. Meling GI, Rognum TO, Clausen OP, Børmer O, Lunde OC, Schlichting E, et al. Serum carcinoembryonic antigen in relation to survival, DNA ploidy pattern, and recurrent disease in 406 colorectal carcinoma patients. Scandinavian Journal of Gastroenterology 1992 Dec;27(12):1061-8.
170. Mentges B, Grussner R, Klotter HJ, Batz W. 10 years experience with CEA in the postoperative monitoring of patients undergoing surgery to cure colorectal carcinomas. Acta Medica Austriaca 1986;13:93-4.
171. Mentges B. [Effect of serial CEA determination on diagnosis, therapy and prognosis of recurrent colorectal cancer]. Langenbecks Archiv für Chirurgie 1988;373(4):227-34.
172. Metzger U, Decurtins M, Joller H. Carcinoembryonic antigen (CEA) in large bowel cancer treated by surgery [[German] Das karzinoembryonale antigen (Cea) beim operierten dickdarmkarzinom]. schweizerische medizinische wochenschrift 1983;113(15):548-9.
173. Metzger U, Bronz K, Buhler H, Dolder A, Seefeld U, Hollinger A, et al. [Prospective follow-up study of radically resected colorectal carcinoma. Status after 5 years]. Schweizerische Medizinische Wochenschrift Journal Suisse de Medecine 1985;115(29):1001-4.
174. Minton JP, James KK, Hurtubise PE, Rinker L, Joyce S, Martin EW, Jr. The use of serial carcinoembryonic antigen determinations to predict recurrence of carcinoma of the colon and the time for a second-look operation. Surgery, Gynecology & Obstetrics 1978;147(2):208-10.
175. Minton JP, Martin EW Jr. The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation. Cancer 1978;42(3 Suppl):1422-7.
176. Minton J, Chevinsky AH. CEA directed second-look surgery for colon and rectal cancer. Chirurgiae et Gynaecologiae 1989;78(1):32-7.
177. Miwa Y. Serum CEA levels in various gastrointestinal diseases with special reference to colorectal cancer. Japanese Journal of Gastroenterology 1980;77(7):1069-75.
178. Moertel CG, Schutt AJ, Go VL. Carcinoembryonic antigen test for recurrent colorectal carcinoma. JAMA 1978;239(11):1065-6.
179. Morelli M, Nardi M, Valle M, Balducci D, Serafini D, Bernardini P. [Experience in the use of the tumor markers CEA, GICA and TPA in the postoperative monitoring of colorectal neoplasms]. Minerva Medica 1985;76:34-35.
180. Moreno Carretero G, Cerdan Miguel FJ, Maestro de las Casas ML, Martinez Cortijo S, Ortega MD, Pardo Martinez M, et al. Serum and tissue CEA in colorectal cancer: clinical relevance. Revista Espanola de Enfermedades Digestivas 1998;90(6):391-401.
181. Moschl P, Staritz C, Keiler A, Kreuzer W, Fasching W. [Carcino-embryonic antigen as screening protein in the follow-up of patients with surgically-treated gastrointestinal cancer (author's transl)]. Wiener Klinische Wochenschrift 1980;92(4):128-30.
182. Nicolini A, Caciagli M, Zampieri F, Ciampalini G, Carpi A, Spisni R, et al. Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. Cancer Detection & Prevention 1995;19(2):183-95.
183. Nicolini A, Ferrari P, Anselmi L, Metelli MR, Carpi A, Spisni R, et al. Recurrences of colorectal cancer: time distribution and diagnostic sensitivity of serum CEA, TPA, CA19.9, CA72.4 tumour markers. Journal of Clinical Oncology 2005;23(16):301S-S.
184. Nicolini A, Ferrari P, Duffy MJ, Antonelli A, Rossi G, Metelli MR, et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Archives of Surgery 2010;145(12):1177-83.
185. Northover JM. Carcinoembryonic antigen and recurrent colorectal cancer. British Journal of Surgery 1985;Suppl:S44-6.
186. Northover J. Carcinoembryonic antigen and recurrent colorectal cancer. Gut 1986;27(2):117-22.
187. Northover J. Follow-up after curative surgery for colorectal cancer. Scandinavian Journal of Surgery: SJS 2003;92(1):84-9.
188. Novis BH, Gluck E, Thomas P, Steele GD, Zurawski VR Jr, Stewart R, et al. Serial levels of CA 19-9 and CEA in colonic cancer. Journal of Clinical Oncology 1986;4(6):987-93.
189. Nowacki M. [Clinical usefulness of the study of serum carcinoembryonic antigen (CEA) for the determination of the degree of tumor progression, prognosis and monitoring of surgical treatment of neoplasms of the large intestine]. Nowotwory 1983;33(1):13-26.
190. Ntinas A, Zambas N, Al Mogrambi S, Petras P, Chalvatzoulis E, Frangandreas G, et al. Postoperative follow-up of patients with colorectal cancer: a combined evaluation of CT scan, colonoscopy and tumour markers. Techniques in Coloproctology 2004;8(Suppl 1):s190-2.
191. O'Dwyer PJ, Mojzisik C, McCabe DP, Sickle-Santanello BJ, Farrar WB, Martin EW Jr. Variation in recognition of recurrent colonic cancer by different CEA assays. Diseases of the Colon and Rectum 1987;30(2):133-6.
192. O'Dwyer PJ, Mojzisik C, McCabe DP, Farrar WB, Carey LC, Martin EW Jr. Reoperation directed by carcinoembryonic antigen level: the importance of a thorough preoperative evaluation. American Journal of Surgery 1988;155(2):227-31.
193. Obradovic VB, Artiko V, Sobic D, Petrovic N, Todorovic-Tirnanic M, Brajkovic L, et al. Diagnosis of recurrences and metastases of colorectal carcinomas using 18FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging 2011;38:S274.
194. Odariuk TS, Sevost'ianov SI, Mit'kov VV, Orlova LP. [A comparative evaluation of methods for diagnosing recurrence of rectal cancer after radical surgery]. Voprosy Onkologii 1989;35(9):1097-103.
195. Ovaska JT, Jarvinen HJ, Mecklin JP. The value of a follow-up programme after radical surgery for colorectal carcinoma. Scandinavian Journal of Gastroenterology 1989;24(4):416-22.
196. Ozhiganov EL, Kuznetsova LF. [Determination of carcinoembryonic and carbohydrate antigens in the diagnosis of recurrences and metastases of rectal cancer]. Meditsinskaia Radiologiia 1986;31(8):40-4.
197. Ozkan E, Soydal C, Araz M, Aras G. Serum carcinoembryonic antigen measurement, abdominal contrast-enhanced computed tomography, and fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in the detection of colorectal cancer recurrence: a correlative study. Nuclear Medicine Communications 2012;33(9):990-4.
198. Ozkan E, Soydal C, Araz M, Kir KM, Ibis E. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels. Nuclear Medicine Communications 21012;33(4):395-402.
199. Park I, You Y, Skibber JM, Rodriguez-Bigas MA, Feig B, Nguyen S, et al. Recurrence patterns after multidisciplinary therapy for rectal cancer in 725 patients. Annals of Surgical Oncology 2012;19:S15-6.
200. Park JW, Chang HJ, Kim BC, Yeo HY, Kim DY. Clinical validity of tissue carcinoembryonic antigen expression as ancillary to serum carcinoembryonic antigen concentration in patients curatively resected for colorectal cancer. Colorectal Disease 2013;15(9):e503-11.
201. Pecorella G, Bracchitta S, Petrolito E, Cacciaguerra B, Blanco F, Cirino E. [Follow up in carcinoma of the large intestine]. Annali Italiani di Chirurgia 1996;67(1):41-7.
202. Peethambaram P, Weiss M, Loprinzi CL, Novotny P, O'Fallon JR, Erlichman C, et al. An evaluation of postoperative follow-up tests in colon cancer patients treated for cure. Oncology 1997;54(4):287-92.
203. Pereira JMC, Martinez C, Pimenta T, Oliveira MC. Carcinoembryonic antigen dosage and colorectal cancer recurrence. Diseases of the Colon and Rectum 2004;47(6):986.
204. Persijn JP, Hart AA. Prognostic significance of CEA in colorectal cancer: a statistical study. Journal of Clinical Chemistry & Clinical Biochemistry 1981;19(11):1117-23.
205. Pfeiffer R, Reis HE, Wittig HD. CEA determination with the Hansen method: Postsurgical follow-up of patients with colorectal carcinoma [[German] Erfahrungen mit der cea-bestimmung bei der postoperativen verlaufskontrolle von patienten mit colorectalem carcinom]. Journal of Cancer Research and Clinical Oncology 1979;93(1):85-92.
206. Phillips RK, Hittinger R, Blesovsky L, Fry JS, Fielding LP. Local recurrence following 'curative' surgery for large bowel cancer: I. The overall picture. British Journal of Surgery 1984;71(1):12-6.
207. Pietra N, Sarli L, Costi R, Ouchemi C, Grattarola M, Peracchia A. Role of follow-up in management of local recurrences of colorectal cancer -A prospective, randomized study. Diseases of the Colon and Rectum 1998;41(9):1127-33.
208. Plebani M, De Paoli M, Basso D, Roveroni G, Giacomini A, Galeotti F, et al. Serum tumor markers in colorectal cancer staging, grading, and follow-up. Journal of Surgical Oncology 1996;62(4):239-44.
209. Pompecki R, Winkler R. Clinical value of serial serum CEA determinations in postoperative follow-up of colorectal cancer [[German] Klinische bedeutung der routinemassigen serum-cea-bestimmung fur die postoperative kontrolle des kolorektalen karzinoms]. Medizinische Welt 1980;31(49):1780-3.
210. Pribelsky M, Pechan J, Krizan M, Pindak D. CEA and relapse after the operation of colorectal carcinoma. Bratislavske Lekarske Listy 2002;103(11):428-31.
211. Primrose JN, Fuller A, Rose P, Perera-Salazar R, Mellor J, Corkhill A, et al. Follow-up after colorectal cancer surgery: Preliminary observational findings from the UK FACS trial. Journal of Clinical Oncology. Chicago: ASCO Annual Meeting 2011, 2011.
212. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014;311(3):263-70.
213. Quentmeier A, Schlag P, Smok M, Herfarth C. Re-operation for recurrent colorectal cancer: the importance of early diagnosis for resectability and survival. European Journal of Surgical Oncology 1990;16(4):319-25.
214. Reddy GA, Abrar ML, Rajender K, Anish B, Mittal BR. Role of FDG PET/CT in evaluation of suspected recurrence of disease in patients of colon carcinoma in relation to carcinoembryonic antigen (CEA) levels. European Journal of Nuclear Medicine and Molecular Imaging 2013;40:S474-S.
215. Revetria P, Repetto L, Perino M, Ciabattoni N, Gambetta G, Ferro A. Postoperative monitoring of carcinoma of the large bowel. Diagnostic and prognostic value of tumor markers CEA, CA 19-9 and TPA. [Italian]. Chirurgia 1989;2(3):121-4.
216. Rezamansourian A, Ghaemi E. The prevalence of elevated carcinoembroynic antigen at Gorgan south-east Caspian sea of Northern Iran. Journal of Clinical and Diagnostic Research 2011;5(1):74-7.
217. Rieger A, Wahren B. CEA levels at recurrence and metastases; importance for detecting secondary disease. Scandinavian Journal of Gastroenterology 1975;10(8):869-74.
218. Rockall TA, McDonald PJ. Carcinoembryonic antigen: its value in the follow-up of patients with colorectal cancer. International Journal of Colorectal Disease 1999;14(1):73-7.
219. Rocklin MS, Slomski CA, Watne AL. Postoperative surveillance of patients with carcinoma of the colon and rectum. American Surgeon 1990;56(1):22-7.
220. Rocklin MS, Senagore AJ, Talbott TM. Role of carcinoembryonic antigen and liver function tests in the detection of recurrent colorectal carcinoma. Diseases of the Colon and Rectum 1991;34(9):794-7.
221. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. Journal of Clinical Oncology 2006;24(3):386-93.
222. Rognum TO, Heier HE, Orjasaeter H, Thorud E, Brandtzaeg P. Comparison of two CEA assays in primary and recurrent large bowel carcinoma with different DNA ploidy pattern. European Journal of Cancer & Clinical Oncology 1986;22(10):1165-9.
223. Sagar PM, Cooper EH, Finan PJ. A prospective assessment of the tumor-markers Ca50, Ca195 and CEA in prediction of tumor stage and recurrence in colorectal-cancer. British Journal of Cancer 1989;60(3):488.
224. Sandelewski A, Kokocinska D, Partyka R, Kocot J, Starzewski J, Chanek I, et al. [Usefulness of evaluation of carcinoembryonic antigen (CEA) and soluble fragments of cytokeratin 18-th (TPS) in postoperative monitoring of patients with colorectal cancer]. Polski Merkuriusz Lekarski 2005;18(108):647-50.
225. Sanli Y, Kuyumcu S, Ozkan ZG, Kilic L, Balik E, Turkmen C, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Annals of Nuclear Medicine 2012;26(7):551-8.
226. Sardi A, Agnone CM, Nieroda CA, Mojzisik C, Hinkle G, Ferrara P, et al. Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination. Southern Medical Journal 1989;82(10):1235-44.
227. Sarikaya I, Bloomston M, Povoski SP, Zhang J, Hall NC, Knopp MV, et al. FDG-PET scan in patients with clinically and/or radiologically suspicious colorectal cancer recurrence but normal CEA. World Journal of Surgical Oncology 2007;5:64.
228. Secco GB, Fardelli R, Campora E, Rovida S, Onetto M, Marroni P, et al. CEA as a prognostic factor and early indicator of recurrence in colorectal cancer. Journal of Experimental and Clinical Cancer Research 1989;8(3):173-7.
229. Secco GB, Fardelli R, Rovida S, Gianquinto D, Baldi E, Bonfante P, et al. Is intensive follow-up really able to improve prognosis of patients with local recurrence after curative surgery for rectal cancer?. Annals of Surgical Oncology 2000;7(1):32-7.
230. Segol PH, Travert G, Davy A. Serum carcinoembryonic antigen determinations during post operative follow up of colorectal carcinomas [[French] Le dosage de l'antigene carcino embryonnaire dans la surveillance post operatoire des cancers colo rectaux]. Lyon Chirurgical 1977;73(4):289-92.
231. Shirley LA, McNally M, Huntington J, Jones N, Malhotra L, Bloomston M, et al. Correlation of postoperative CEA trends with survival and patterns of recurrence after hepatectomy for colorectal cancer metastases. Journal of Clinical Oncology. San Francisco, CA United States: 2012 Gastrointestinal Cancers Symposium, 2012.
232. Simo M, Lomena F, Setoain J, Perez G, Castellucci P, Costansa JM, et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nuclear Medicine Communications 2002;23(10):975-82.
233. Sirisriro R, Podoloff DA, Patt YZ, Curley SA, Kasi LP, Bhadkamkar VA, et al. 99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management. Nuclear Medicine Communications 1996;17(7):568-76.
234. Song S, Minsky B, Polite B, Liauw S. Post-treatment CEA values, and CEA trends at the time of uncertain post-treatment imaging, have prognostic value after combined modality therapy for rectal cancer. International Journal of Radiation Oncology Biology Physics. 52nd Annual Meeting of the American Society for Radiation Oncology, San Diego, CA, USA. 2010:S313.
235. Sorensen NF, Jensen AB, Wille-Jorgensen P, Friberg L, Rordam L, Ingeman L, et al. Strict follow-up programme including CT and 18F-FDG-PET after curative surgery for colorectal cancer. Colorectal Disease 2010;12:e224-8.
236. Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. American Journal of Surgery 1985;149(2):198-104.
237. Staab HJ, Brummendorf T, Hornung A, Anderer FA, Kieninger G. The clinical validity of circulating tumor-associated antigens CEA and CA 19-9 in primary diagnosis and follow-up of patients with gastrointestinal malignancies. Klinische Wochenschrift 1985;63(3):106-15.
238. Stautner-Brückmann C, Schneider W, Gresser U, Richter-Turtur M, Eibl-Eibesfeld B, Zoller WG, et al. Is ultrasound superior to carcinoembryonic antigen (CEA) measurement in recurrent tumor screening of patients with colorectal carcinoma?. Bildgebung 1990;57(1-2):17-20.
239. Steele G Jr, Zamcheck N, Wilson R. Results of CEA-initiated second-look surgery for recurrent colorectal cancer. American Journal of Surgery 1980;139(4):544-8.
240. Stuckle CA, Ibing HP, Adamietz IA. Value of computed tomography and tumor markers in detection of recurrent rectal carcinoma after surgery and radiotherapy [[German] Wertigkeit der computertomographie und der tumormarker zur beurteilung von lokalrezidiven beim operierten und nachbestrahlten rektumkarzinom]. Tumor Diagnostik und Therapie 2000;21(3):61-7.
241. Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World Journal of Gastroenterology 2012;18(17):2121-6.
242. Sugarbaker PH, Zamcheck N, Moore FD. Assessment of serial carcinoembryonic antigen (CEA) assays in postoperative detection of recurrent colorectal cancer. Cancer 1976;38(6):2310-5.
243. Szymendera JJ, Nowacki MP, Szawlowski AW, Kaminska JA. Predictive value of plasma CEA levels: preoperative prognosis and postoperative monitoring of patients with colorectal carcinoma. Diseases of the Colon and Rectum 1982;25(1):46-52.
244. Szymendera JJ, Wilczynska JE, Nowacki MP, Kaminska JA, Szawowski AW. Serial CEA assays and liver scintigraphy for the detection of hepatic metastases from colorectal carcinoma. Diseases of the Colon and Rectum 1982;25(3):191-7.
245. Szymendera JJ, Nowacki MP, Kozlowicz-Gudzinska I, Kowalska M. Value of serum levels of carcinoembryonic antigen, CEA, and gastrointestinal cancer antigen, GICA or CA 19-9, for preoperative staging and postoperative monitoring of patients with colorectal carcinoma. Diseases of the Colon and Rectum 1985;28(12):895-9.
246. Takashima S, Kosaka T, Uemura T. Clinical meanings of carcinoembryonic antigen (CEA) in patients with colorectal cancer. Journal of the Japan Society of Colo-Proctology 1981;35(2):137-46.
247. Tomoda H, Furusawa M. The usefulness and limitations of CEA assay in the management of colorectal cancer. Japanese Journal of Surgery 1981;11(1):33-8.
248. Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, et al. Predictive factors of early relapse in UICC stage I-III colorectal cancer patients after curative resection. Journal of Surgical Oncology 2009;100(8):736-43.
249. Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. Journal of Clinical Oncology 2009;27(22):3671-6.
250. Verberne CJ, Wiggers T, Vermeulen KM, De Jong KP. Detection of recurrences during follow-up after liver surgery for colorectal metastases: both carcinoembryonic antigen (CEA) and imaging are important. Annals of Surgical Oncology 2013;20(2):457-63.
251. Verberne C, Doornbos PM, Grossmann I, De Bock GH, Wiggers T. Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging. European Cancer Congress 2013, ECC 2013, Amsterdam. European Journal of Cancer. 2013; Vol. 49:S480.
252. Wang JY, Tang R, Chiang JM. Value of carcinoembryonic antigen in the management of colorectal cancer. Diseases of the Colon and Rectum 1994 Mar;37(3):272-7.
253. Wanebo HJ, Rao B, Pinsky CM, Hoffman RG, Stearns M, Schwartz MK, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. New England Journal of Medicine 1978;299(9):448-51.
254. Wanebo JH, Stearns M, Schwartz MK. Use of CEA as an indicator of early recurrence and as a guide to a selected second-look procedure in patients with colorectal cancer. Annals of Surgery 1978;188(4):481-93.
255. Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, et al. Prognostic significance of pre-and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. European Surgical Research 2007;39(4):245-50.
256. Wang ZY. Serum p53 antibody as a tumor marker in the follow-up of colorectal cancer after curative resection. Techniques in Coloproctology 2010;14(1):57-8.
257. Wedell J, Meier zu Esssen P, Luu TH, Fiedler R, Van Calker H, Koldowski P, et al. A retrospective study of serial CEA determinations in the early detection of recurrent colorectal cancer. Diseases of the Colon and Rectum 1981;24(8):618-21.
258. Weiss NS, Cook LS. Evaluating the efficacy of screening for recurrence of cancer. Journal of the National Cancer Institute 1998;90(24):1870-2.
259. Wichmann MW, Lau-Werner U, Müller C, Hornung HM, Stieber P, Schildberg FW, et al. Carcinoembryonic antigen for the detection of recurrent disease following curative resection of colorectal cancer. Anticancer Research 2000;20(6D):4953-5.
260. Wichmann MW, Müller C, Lau-Werner U, Strauss T, Lang RA, Hornung HM, et al. The role of carcinoembryonic antigen for the detection of recurrent disease following curative resection of large-bowel cancer. Langenbecks Archives of Surgery 2000;385(4):271-5.
261. Wichmann MW, Müller C, Hornung HM, Lau-Werner U, Schildberg FW, Colorectal Cancer Study G. Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World Journal of Surgery 2002;26(6):732-6.
262. Wolf RF, Cohen AM. The miniscule benefit of serial carcinoembryonic antigen monitoring after effective curative treatment for primary colorectal cancer. Journal of the American College of Surgeons 1997;185(1):60-4.
263. Wood CB, Malcolm AJH, Burt R. Assessment of patients with elevated carcinoembryonic antigen (CEA) level after surgery for primary colorectal cancer. Bulletin de la Societe Internationale de Chirurgie 11975;34(6):413-6.
264. Yu H, Zhao M, Xing J, Jin H, Li Y. Relationship of the applied value of 18F-FDG PET/CT in postoperative relapse with metastasis of colorectal cancer and CEA levels during PET/CT scanning. Chinese Journal of Clinical Oncology 2013;40(12):717-20.
265. Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Diseases of the Colon and Rectum 1993;36(11):1063-8.
266. Zervos EE, Badgwell BD, Burak WE Jr, Arnold MW, Martin EW. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 2001;130(4):636-43.
267. Ziegenbein R, Jacobasch KH, Pilgrim G, Seifart W. [The CEA-concentration in plasma of patients with colorectal carcinoma and polyps has been determined by radioimmunoassay (RIA, Z-gel-method)]. Archiv für Geschwulstforschung 1980;50(2):165-8.
268. Zuniga A, Rahmer A, Guzman S, Llanos O, Lopez F, Herreros R. [Colorectal cancer: follow-up after curative resection]. Revista Medica de Chile 1989;117(3):273-8.
269. Allen VB, Gurusamy KS, Takwoingi Y, Kalia A, Davidson BR. Diagnostic accuracy of laparoscopy following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD009323.pub2]
270. Bormer OP. Standardization, specificity, and diagnostic sensitivity of four immunoassays for carcinoembryonic antigen. Clinical Chemistry 1991;37(2):231-6.
271. Colibaseanu DT, Mathis KL, Abdelsattar ZM, Larson DW, Haddock MG, Dozois EJ. Is curative resection and long-term survival possible for locally re-recurrent colorectal cancer in the pelvis?. Diseases of the Colon and Rectum 2013;56(1):14-9.
272. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375(9719):1030-47.
273. Dallas MR, Liu G, Chen W, Thomas SN, Wirtz D, Huso DL, et al. Divergent roles of CD44 and carcinoembryonic antigen in colon cancer metastasis. FASEB Journal 2012;26(6):2648-56.
274. Davidson BR, Sams VR, Styles J, Dean C, Boulos PB. Comparative study of carcinoembryonic antigen and epithelial membrane antigen expression in normal colon, adenomas and adenocarcinomas of the colon and rectum. Gut 1989;30(9):1260-5.
275. Deeks JJ, Mackaskil P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology 2005;58(9):882-93.
276. Duffy MJ. Tumor markers in clinical practice: a review focusing on common solid cancers. Medical Principles and Practice 2013;22(1):4-11.
277. Duffy MJ, Lamerz R, Haglund C, NIcolini A, Kalousova M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European Group on Tumour Markers (EGTM) 2014 Guidelines Update. International Journal of Cancer 2013;134(11):2513-22. [DOI: 10.1002/ijc.28384]
278. Dukes CE. The classification of cancer of the rectum. Journal of Pathological Bacteriology 1932;35:323-32.
279. Ferlay I, Soerjomataram, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 31 March 2014.
280. Glimelius B, Påhlman L, Graf W, Tveit K, Adami HO, Iasarett V, et al. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Journal of Clinical Oncology 1992;10(6):904-11.
281. Godlee F. Colorectal cancer: a cautionary tale. BMJ 2014;348:g3311.
282. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Investigations 2005;23(4):339-51.
283. Gonzalez M, Poncet A, Combescure C, Robert J, Ris HB, Gervaz P. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Annals of Surgical Oncology 2013;20(2):572-9.
284. Gore RM. Colorectal cancer. Clinical and pathologic features. Radiological Clinics of North America 1997;35(2):403-29.
285. Guthrie JA. Colorectal cancer: follow-up and detection of recurrence. Abdominal Imaging 2002;27(5):570-7.
286. Hamza TH, Arends LR, Van Houwelingen HC, Stijnen T. Multivariate random effects meta-analysis of diagnostic tests with multiple thresholds. BMC Medical Research Methodology 2009;9(73):1-15.
287. Jeffery M, Hickey BE, Hilder PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD002200.pub2]
288. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clinical Epidemiology 201;4:283-301.
289. Kjeldsen BJ, Kronborg O, Fenger C, Jørgensen OD. A prospective randomised study of follow-up after radical surgery for colorectal cancer. British Journal of Surgery 1997;84:666-9.
290. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. Primary colon cancer: ESMO Clinical Practice Guidelines for Diagnosis, adjuvant treatment and follow-up. Annals of Oncology 2010;21(Suppl 5):v70-v77.
291. Laurence DJ, Turberville C, Anderson SG, Neville AM. First British standard for carcinoembryonic antigen (CEA). British Journal of Cancer 1975;32(3):295-9.
292. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic review of diagnostic test accuracy. Annals of Internal Medicine 2008;149(12):889-97.
293. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, MacDonald JS, et al. ASCO 2006 update of Recommendations for the use of tumour markers in gastrointestinal cancer. Journal of Clinical Oncology 2006;24(33):5313-27.
294. Macakill P, Gatonis C, Deeks JJ, Harbord RM, Takwoingi Y (editors). Chapter 10: Analysing and presenting results. In: Cochrane Handbook for Systematic Reviews of Test Accuracy Version 1.0, 2010. Available from dta.cochrane.org/handbook-dta-reviews. The Cochrane Collaboration.
295. Maringe C, Walters S, Rachet B, Butler J, Fields T, Finan P, et al. Stage at diagnosis and colorectal cancer survival in six high-income countries: A population-based study of patients diagnosed during 2000-2007. Acta Oncologica 2013;52(5):919-32.
296. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Statistics in Medicine 1993;12(14):1293-316.
297. NCCN 2013. NCCN Guidelines Version 3.2013 Colon Cancer. NCCN Clinical Practice Guidelines in Oncology 2013.
298. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Disease 2011;14(1):3-17.
299. NICE clinical guideline [CG131]. Colorectal Cancer; diagnosis and management. www.nice.org.uk/guidance/cg131/chapter/1-recommendations 2011 (accessed 5th December 2015).
300. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology 2005;58(10):982-90.
301. Rodriguez-Moranta F, Salo J, Arcusa A, Boadas J, Pinol V, Bessa X, et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: A prospective, multicenter, randomised, controlled trial. Journal of Clinical Oncology 2005;24(1):1-8.
302. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data From 20, 898 patients enrolled onto 18 randomized trials from the ACCENT group. Journal of Clinical Oncology 2007;25(29):4569-74.
303. Scheer A, Auer RAC. Surveillance after curative resection of colorectal cancer. Clinics in Colon and Rectal Surgery 2009;22(4):242-50.
304. Schoemaker D, Black R, Giles L, Toouli J. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal patients. Gastroenterology 1998;114:7-14.
305. Secco GB, Fardelli RM, Gianquinto D, Bonfante P, Baldi E, Ravera G, et al. Efficacy and cost of risk adapted follow-up in patients after colorectal surgery: a prospective, randomised and controlled trial. European Journal of Surgical Oncology 2002;28:418-23.
306. Shinkins B, Nicholson BD, James TJ, Primrose JN, Mant D. Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the results?. Clinical Chemistry 2014;60(12):1572-4.
307. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumours. 7. Wiley-Blackwell, 2009.
308. Song F, Khan KS, Dinnes J, Sutton AJ. Asymmetric funnel plots and publication bias in meta-analysis of diagnostic accuracy. International Journal of Epidemiology 2002;31(1):88-95.
309. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009;339:852-8.
310. Takwoingi Y. Meta-analysis of test accuracy studies in Stata: a bivariate model approach. Available from: srdta.cochrane.org/ November 2013, issue Version 1.0.
311. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surgical Oncology 2009;18(1):15-24.
312. Treasure T, Monson K, Fiorentino F, Russell C. The CEA Second-Look Trial:a randomised controlled trial of carcinoembryonic antigen prompted reoperation for recurrent colorectal cancer. BMJ Open 2014;4:e004385.
313. Van Roon AHC, Van Dam L, Zauber AG, Van Ballegooijen M, Borsboom GJJM, Steyerberg EW, et al. Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI: 10.1002/14651858.CD009276]
314. Wattchow DA, Weller DP, Esterman A, Pilotto LS, McGorm K, Hammett Z, et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. British Journal of Cancer 2006;94(8):1116-21.
315. Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine 2011;155(8):529-36.
316. Wild D. The Immunoassay Handbook: Theory and Applications of Ligand Binding, ELISA and Related Techniques. 4th Edition. Elsevier, 31 Jan 2013.